Ropocamptide

Summary

Ropocamptide (omiganan pentahydrochloride) is an investigational synthetic antimicrobial peptide developed for topical application. It has been studied for prevention of catheter-related infections, rosacea, and atopic dermatitis. It reached Phase III clinical trials for central venous catheter site antisepsis and has been investigated for inflammatory dermatological conditions.

Mechanism of Action

Ropocamptide (also known as omiganan) is a synthetic cationic antimicrobial peptide derived from indolicidin. It disrupts bacterial cell membranes by inserting into and destabilizing the lipid bilayer of gram-positive and gram-negative bacteria, as well as fungi, leading to cell lysis and death. It does not rely on a specific receptor target, reducing the likelihood of classical resistance development.

Routes of Administration

Goals & Uses

• Broad-spectrum topical antimicrobial activityAnti InfectiveModerate
• Treatment of rosaceaDermatologyModerate
• Treatment of atopic dermatitisImmunology / DermatologyLow
• Acne vulgaris treatmentDermatologyLow
• Prevention of catheter-related bloodstream infectionsAnti Infective / ProphylaxisModerate

Contraindications

• Known hypersensitivity to omiganan or related peptidesAllergyHigh
• Application to open wounds or mucous membranes (unless studied)SafetyModerate

Adverse Effects

• Local skin irritationDermatologicalCommon
• Skin drynessDermatologicUncommon
• PruritusDermatologicCommonItching
• Contact dermatitisDermatologicalUncommon

Drug Interactions

• Other topical antimicrobialsLow

Population Constraints

• Pediatric populationsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with compromised skin barrierDisease RelatedRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; clinical trials conducted in European centers.
• United StatesInvestigationalNo FDA approval; investigated under IND for catheter antisepsis and dermatological conditions.
• United KingdomUnknownNo known MHRA approval; regulatory status post-Brexit not specifically documented.

Ropocamptide has not received FDA or EMA approval as of the knowledge cutoff. It completed Phase III trials for catheter-site antisepsis (sponsored by Cadence Pharmaceuticals/Migenix) without gaining approval. More recent development has focused on dermatological indications under different sponsors.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions